Gene Editing Firm Editas Medicine Raises $43M in Series A Round | GenomeWeb

NEW YORK (GenomeWeb News) – Gene editing firm Editas Medicine today announced it has secured $43 million in Series A financing.

The financing was led by Flagship Ventures, Polaris Partners, and Third Rock Ventures. Partners Innovation Fund also participated.

Editas plans to use its genome editing technology to develop new therapeutics “that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.